Vion Pharmaceuticals Inc has executed a Clinical Trials Agreement for its anti-cancer drug Triapine with the Cancer Therapy Evaluation Program of the National Cancer Institute's (NCI) Division of Cancer Treatment and Diagnosis. The Clinical Trials Agreement covers the conduct of future trials sponsored by the NCI to explore the activity of Triapine as a single agent or in combination with other agents in patients with cancer.
Initial approval by the NCI to collaborate with Vion on the development of Triapine was announced by Vion in November 2002.
Vion Pharmaceuticals is a biotechnology company developing novel agents for the treatment of cancer. Vion's portfolio of agents includes: Triapine, a potent inhibitor of a key step in DNA synthesis and repair; VNP40101M, a unique DNA alkylating agent; and Tapet, a modified Salmonella vector used to deliver anticancer agents directly to tumors.